多粘菌素B在肾细胞中的摄取。
Uptake of polymyxin B into renal cells.
作者信息
Abdelraouf Kamilia, Chang Kai-Tai, Yin Taijun, Hu Ming, Tam Vincent H
机构信息
Department of Pharmacological and Pharmaceutical Sciences, University of Houston College of Pharmacy, Houston, Texas, USA.
Department of Clinical Sciences and Administration, University of Houston College of Pharmacy, Houston, Texas, USA.
出版信息
Antimicrob Agents Chemother. 2014 Jul;58(7):4200-2. doi: 10.1128/AAC.02557-14. Epub 2014 Apr 14.
Abstract
Polymyxin B is increasingly used as a treatment of last resort against multidrug-resistant Gram-negative infections. Using a mammalian kidney cell line, we demonstrated that polymyxin B uptake into proximal tubular epithelial cells was saturable and occurred primarily through the apical membrane, suggesting the involvement of transporters in the renal uptake of polymyxin B. Megalin might play a role in the uptake and accumulation of polymyxin B into renal cells.
摘要
多粘菌素B越来越多地被用作治疗多重耐药革兰氏阴性菌感染的最后手段。我们使用一种哺乳动物肾细胞系证明，多粘菌素B进入近端肾小管上皮细胞的过程是可饱和的，且主要通过顶膜发生，这表明转运体参与了多粘菌素B的肾脏摄取过程。巨膜蛋白可能在多粘菌素B摄取并积聚到肾细胞的过程中发挥作用。
相似文献
1
Uptake of polymyxin B into renal cells.
Antimicrob Agents Chemother. 2014 Jul;58(7):4200-2. doi: 10.1128/AAC.02557-14. Epub 2014 Apr 14.
2
Measuring polymyxin uptake by renal tubular cells: is BODIPY-polymyxin B an appropriate probe?
Antimicrob Agents Chemother. 2014 Oct;58(10):6337-8. doi: 10.1128/AAC.03733-14.
3
Reply to "measuring polymyxin uptake by renal tubular cells: is BODIPY-polymyxin B an appropriate probe?".
Antimicrob Agents Chemother. 2014 Oct;58(10):6339. doi: 10.1128/AAC.03784-14.
4
Mechanisms of gelofusine protection in an in vitro model of polymyxin B-associated renal injury.
Am J Physiol Renal Physiol. 2024 Jul 1;327(1):F137-F145. doi: 10.1152/ajprenal.00029.2024. Epub 2024 May 23.
5
Cellular Uptake and Localization of Polymyxins in Renal Tubular Cells Using Rationally Designed Fluorescent Probes.
Antimicrob Agents Chemother. 2015 Dec;59(12):7489-96. doi: 10.1128/AAC.01216-15. Epub 2015 Sep 21.
6
Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms.
Expert Opin Investig Drugs. 2008 May;17(5):661-8. doi: 10.1517/13543784.17.5.661.
7
Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections.
J Antimicrob Chemother. 2004 Aug;54(2):566-9. doi: 10.1093/jac/dkh369. Epub 2004 Jul 21.
8
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
J Antimicrob Chemother. 2007 Dec;60(6):1206-15. doi: 10.1093/jac/dkm357. Epub 2007 Sep 17.
9
Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series.
Ann Pharmacother. 2008 Sep;42(9):1177-87. doi: 10.1345/aph.1K346. Epub 2008 Jul 29.
10
Clinical Use of Polymyxin B.
Adv Exp Med Biol. 2019;1145:197-218. doi: 10.1007/978-3-030-16373-0_14.
引用本文的文献
1
: Epidemiology and resistance evolution of an emerging zoonotic bacteria.
One Health. 2025 Jun 16;21:101098. doi: 10.1016/j.onehlt.2025.101098. eCollection 2025 Dec.
2
Evaluating nephrotoxicity reduction in a novel polymyxin B formulation: insights from a 3D kidney-on-a-chip model.
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0021924. doi: 10.1128/aac.00219-24. Epub 2024 Sep 3.
3
Genetic predisposition and high exposure to colistin in the early treatment period as independent risk factors for colistin-induced nephrotoxicity.
Clin Transl Sci. 2024 Mar;17(3):e13764. doi: 10.1111/cts.13764.
4
Recent Advances in the Development of Polymyxin Antibiotics: 2010-2023.
ACS Infect Dis. 2024 Apr 12;10(4):1056-1079. doi: 10.1021/acsinfecdis.3c00630. Epub 2024 Mar 12.
5
Interactions Between Antimicrobial Peptides and Targets Responsible for their Nephrotoxic Action: Molecular Dynamics Simulations.
Curr Drug Saf. 2024;19(3):342-349. doi: 10.2174/1574886318666230905100924.
6
Mid-dosing interval concentration is important for polymyxin B exposure and acute kidney injury in critically ill patients.
CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1911-1921. doi: 10.1002/psp4.13040. Epub 2023 Sep 17.
7
Synthesis and Evaluation of Polymyxins Bearing Reductively Labile Disulfide-Linked Lipids.
J Med Chem. 2022 Dec 8;65(23):15878-15892. doi: 10.1021/acs.jmedchem.2c01528. Epub 2022 Nov 18.
8
Effect of Different Dosage Frequency of Polymyxin B on Rat Nephrotoxicity.
Drug Des Devel Ther. 2021 Feb 16;15:611-616. doi: 10.2147/DDDT.S287332. eCollection 2021.
9
Emerging peptide antibiotics with therapeutic potential.
Med Drug Discov. 2021 Mar;9:100078. doi: 10.1016/j.medidd.2020.100078. Epub 2020 Dec 30.
10
In vitro mechanistic studies on α-amanitin and its putative antidotes.
Arch Toxicol. 2020 Jun;94(6):2061-2078. doi: 10.1007/s00204-020-02718-1. Epub 2020 Mar 19.
本文引用的文献
1
Megalin contributes to kidney accumulation and nephrotoxicity of colistin.
Antimicrob Agents Chemother. 2013 Dec;57(12):6319-24. doi: 10.1128/AAC.00254-13. Epub 2013 Oct 7.
2
Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.
Clin Infect Dis. 2013 Nov;57(9):1300-3. doi: 10.1093/cid/cit453. Epub 2013 Jul 9.
3
A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies.
J Antimicrob Chemother. 2013 May;68(5):1104-10. doi: 10.1093/jac/dks536. Epub 2013 Jan 22.
4
Gentamicin binds to the megalin receptor as a competitive inhibitor using the common ligand binding motif of complement type repeats: insight from the nmr structure of the 10th complement type repeat domain alone and in complex with gentamicin.
J Biol Chem. 2013 Feb 8;288(6):4424-35. doi: 10.1074/jbc.M112.434159. Epub 2012 Dec 27.
5
Pharmacokinetics and renal disposition of polymyxin B in an animal model.
Antimicrob Agents Chemother. 2012 Nov;56(11):5724-7. doi: 10.1128/AAC.01333-12. Epub 2012 Aug 20.
6
Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design.
Antimicrob Agents Chemother. 2012 Sep;56(9):4625-9. doi: 10.1128/AAC.00280-12. Epub 2012 Jun 11.
7
Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy.
J Infect. 2012 Jul;65(1):80-7. doi: 10.1016/j.jinf.2012.01.015. Epub 2012 Feb 2.
8
Variability of polymyxin B major components in commercial formulations.
Int J Antimicrob Agents. 2010 Mar;35(3):308-10. doi: 10.1016/j.ijantimicag.2009.11.005. Epub 2009 Dec 31.
9
In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa.
Int J Antimicrob Agents. 2008 Nov;32(5):437-40. doi: 10.1016/j.ijantimicag.2008.05.006. Epub 2008 Aug 19.
10
Clinical and economic impact of common multidrug-resistant gram-negative bacilli.
Antimicrob Agents Chemother. 2008 Mar;52(3):813-21. doi: 10.1128/AAC.01169-07. Epub 2007 Dec 10.
Zotero 插件